First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

Abstract Background NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we present outcomes from a phase I trial of NEO-201 in...

Full description

Bibliographic Details
Main Authors: Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Cancer immunotherapy
Monoclonal antibody
O-glycan
Antibody-dependent cellular cytotoxicity
NEO-201
Regulatory T cells
Online Access:https://doi.org/10.1186/s13046-023-02649-6

Internet

https://doi.org/10.1186/s13046-023-02649-6

Similar Items